ZA200005243B - Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase. - Google Patents
Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase. Download PDFInfo
- Publication number
- ZA200005243B ZA200005243B ZA200005243A ZA200005243A ZA200005243B ZA 200005243 B ZA200005243 B ZA 200005243B ZA 200005243 A ZA200005243 A ZA 200005243A ZA 200005243 A ZA200005243 A ZA 200005243A ZA 200005243 B ZA200005243 B ZA 200005243B
- Authority
- ZA
- South Africa
- Prior art keywords
- group
- nitrobenzamide
- substituted
- hydroxy
- lower alkyl
- Prior art date
Links
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 title description 10
- 239000003112 inhibitor Substances 0.000 title description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 103
- -1 isothioureido group Chemical group 0.000 claims description 66
- 150000001875 compounds Chemical class 0.000 claims description 51
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 50
- 150000003839 salts Chemical class 0.000 claims description 43
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 41
- 125000005843 halogen group Chemical group 0.000 claims description 40
- 125000003545 alkoxy group Chemical group 0.000 claims description 37
- 125000000623 heterocyclic group Chemical group 0.000 claims description 33
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 32
- 125000003118 aryl group Chemical group 0.000 claims description 29
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 24
- 125000002252 acyl group Chemical group 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 125000003277 amino group Chemical group 0.000 claims description 18
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 16
- 125000002837 carbocyclic group Chemical group 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 125000001424 substituent group Chemical group 0.000 claims description 15
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 125000002947 alkylene group Chemical group 0.000 claims description 10
- 229920006395 saturated elastomer Polymers 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 125000004423 acyloxy group Chemical group 0.000 claims description 8
- 125000004414 alkyl thio group Chemical group 0.000 claims description 8
- 125000004104 aryloxy group Chemical group 0.000 claims description 8
- 125000006575 electron-withdrawing group Chemical group 0.000 claims description 8
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 5
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000005530 alkylenedioxy group Chemical group 0.000 claims description 4
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 4
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 4
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 125000004043 oxo group Chemical group O=* 0.000 claims description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 229940002612 prodrug Drugs 0.000 claims description 3
- 239000000651 prodrug Substances 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 201000001881 impotence Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 5
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims 5
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 4
- 206010002383 Angina Pectoris Diseases 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 3
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 3
- 208000010412 Glaucoma Diseases 0.000 claims 3
- 208000022461 Glomerular disease Diseases 0.000 claims 3
- 206010019280 Heart failures Diseases 0.000 claims 3
- 206010020772 Hypertension Diseases 0.000 claims 3
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 3
- 208000001647 Renal Insufficiency Diseases 0.000 claims 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims 3
- 208000006011 Stroke Diseases 0.000 claims 3
- 208000024780 Urticaria Diseases 0.000 claims 3
- 201000010105 allergic rhinitis Diseases 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 210000004204 blood vessel Anatomy 0.000 claims 3
- 206010006451 bronchitis Diseases 0.000 claims 3
- 231100000852 glomerular disease Toxicity 0.000 claims 3
- 230000010243 gut motility Effects 0.000 claims 3
- 208000028774 intestinal disease Diseases 0.000 claims 3
- 201000006370 kidney failure Diseases 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 208000002815 pulmonary hypertension Diseases 0.000 claims 3
- 230000002829 reductive effect Effects 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 208000002249 Diabetes Complications Diseases 0.000 claims 2
- 206010012655 Diabetic complications Diseases 0.000 claims 2
- 206010057671 Female sexual dysfunction Diseases 0.000 claims 2
- 206010021639 Incontinence Diseases 0.000 claims 2
- 208000021891 Micturition disease Diseases 0.000 claims 2
- 125000006308 propyl amino group Chemical group 0.000 claims 2
- 210000002700 urine Anatomy 0.000 claims 2
- WMVCYHPZTMBNQE-UHFFFAOYSA-N 2-(1,3-dihydroxypropan-2-ylamino)-n-[(3-fluoro-4-methoxyphenyl)methyl]-5-nitrobenzamide Chemical compound C1=C(F)C(OC)=CC=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1NC(CO)CO WMVCYHPZTMBNQE-UHFFFAOYSA-N 0.000 claims 1
- FZIYPYIDQKSWSY-UHFFFAOYSA-N 2-(cyclopentylamino)-5-nitro-n-(2-phenylethyl)benzamide Chemical compound C=1C=CC=CC=1CCNC(=O)C1=CC([N+](=O)[O-])=CC=C1NC1CCCC1 FZIYPYIDQKSWSY-UHFFFAOYSA-N 0.000 claims 1
- FZDRTFFISVBGDW-UHFFFAOYSA-N 2-(cyclopentylamino)-5-nitro-n-(3-phenylpropyl)benzamide Chemical compound C=1C=CC=CC=1CCCNC(=O)C1=CC([N+](=O)[O-])=CC=C1NC1CCCC1 FZDRTFFISVBGDW-UHFFFAOYSA-N 0.000 claims 1
- YDLMWCKEAWQSKF-UHFFFAOYSA-N 2-(cyclopentylamino)-n-[(2,4-dichlorophenyl)methyl]-5-nitrobenzamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1CNC(=O)C1=CC([N+](=O)[O-])=CC=C1NC1CCCC1 YDLMWCKEAWQSKF-UHFFFAOYSA-N 0.000 claims 1
- BYTQXWFAXCRYRE-UHFFFAOYSA-N 2-(cyclopentylamino)-n-[(2,4-difluorophenyl)methyl]-5-nitrobenzamide Chemical compound C=1C=C(F)C=C(F)C=1CNC(=O)C1=CC([N+](=O)[O-])=CC=C1NC1CCCC1 BYTQXWFAXCRYRE-UHFFFAOYSA-N 0.000 claims 1
- UMOJWSKVZZEWRW-UHFFFAOYSA-N 2-(cyclopentylamino)-n-[(3,4-dichlorophenyl)methyl]-5-nitrobenzamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1CNC(=O)C1=CC([N+](=O)[O-])=CC=C1NC1CCCC1 UMOJWSKVZZEWRW-UHFFFAOYSA-N 0.000 claims 1
- CBBLQMYIPFUJAG-UHFFFAOYSA-N 2-(cyclopentylamino)-n-[(4-fluorophenyl)methyl]-5-nitrobenzamide Chemical compound C=1C=C(F)C=CC=1CNC(=O)C1=CC([N+](=O)[O-])=CC=C1NC1CCCC1 CBBLQMYIPFUJAG-UHFFFAOYSA-N 0.000 claims 1
- NAANHMUGHHOKHH-UHFFFAOYSA-N 2-(cyclopentylamino)-n-[(4-methoxyphenyl)methyl]-5-nitrobenzamide Chemical compound C1=CC(OC)=CC=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1NC1CCCC1 NAANHMUGHHOKHH-UHFFFAOYSA-N 0.000 claims 1
- YFULYEUXQONKTI-SJLPKXTDSA-N 2-[[(1r,2r)-2-aminocyclohexyl]amino]-n-(1,3-benzodioxol-5-ylmethyl)-5-nitrobenzamide Chemical compound N[C@@H]1CCCC[C@H]1NC1=CC=C([N+]([O-])=O)C=C1C(=O)NCC1=CC=C(OCO2)C2=C1 YFULYEUXQONKTI-SJLPKXTDSA-N 0.000 claims 1
- KLGQWSOYKYFBTR-UHFFFAOYSA-N 2-nitrobenzamide Chemical compound NC(=O)C1=CC=CC=C1[N+]([O-])=O KLGQWSOYKYFBTR-UHFFFAOYSA-N 0.000 claims 1
- OYFHUENOVFSNJC-UHFFFAOYSA-N 5-bromo-n-[(3-chloro-4-methoxyphenyl)methyl]-2-(cyclopentylamino)benzamide Chemical compound C1=C(Cl)C(OC)=CC=C1CNC(=O)C1=CC(Br)=CC=C1NC1CCCC1 OYFHUENOVFSNJC-UHFFFAOYSA-N 0.000 claims 1
- YKUXOXMTEPILCZ-CYBMUJFWSA-N 5-cyano-n-[(3,4-dimethoxyphenyl)methyl]-2-[[(2r)-1-hydroxypropan-2-yl]amino]benzamide Chemical compound C1=C(OC)C(OC)=CC=C1CNC(=O)C1=CC(C#N)=CC=C1N[C@H](C)CO YKUXOXMTEPILCZ-CYBMUJFWSA-N 0.000 claims 1
- YKUXOXMTEPILCZ-ZDUSSCGKSA-N 5-cyano-n-[(3,4-dimethoxyphenyl)methyl]-2-[[(2s)-1-hydroxypropan-2-yl]amino]benzamide Chemical compound C1=C(OC)C(OC)=CC=C1CNC(=O)C1=CC(C#N)=CC=C1N[C@@H](C)CO YKUXOXMTEPILCZ-ZDUSSCGKSA-N 0.000 claims 1
- AJXKKMOLFAOVMB-CTYIDZIISA-N C1=C(Cl)C(OC)=C(Cl)C=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1N[C@@H]1CC[C@@H](O)CC1 Chemical compound C1=C(Cl)C(OC)=C(Cl)C=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1N[C@@H]1CC[C@@H](O)CC1 AJXKKMOLFAOVMB-CTYIDZIISA-N 0.000 claims 1
- IWDJYYHPDSLWOZ-KOMQPUFPSA-N C1=C(Cl)C(OC)=CC=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1N[C@@H]1CC[C@@H](O)CC1 Chemical compound C1=C(Cl)C(OC)=CC=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1N[C@@H]1CC[C@@H](O)CC1 IWDJYYHPDSLWOZ-KOMQPUFPSA-N 0.000 claims 1
- HZAGVTGJPVMJJM-GRGXKFILSA-N C1=C(Cl)C(OC)=CC=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1N[C@@H]1CC[C@H](OC(=O)C=2C=CC=CC=2)CC1 Chemical compound C1=C(Cl)C(OC)=CC=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1N[C@@H]1CC[C@H](OC(=O)C=2C=CC=CC=2)CC1 HZAGVTGJPVMJJM-GRGXKFILSA-N 0.000 claims 1
- UNXYTMYCUFLUQN-GRGXKFILSA-N C1=C(F)C(OC)=CC=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1N[C@@H]1CC[C@H](OC(=O)C=2C=CC=CC=2)CC1 Chemical compound C1=C(F)C(OC)=CC=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1N[C@@H]1CC[C@H](OC(=O)C=2C=CC=CC=2)CC1 UNXYTMYCUFLUQN-GRGXKFILSA-N 0.000 claims 1
- WEXXUEOCMIXDOW-WKILWMFISA-N C1=C(OC)C(OC)=CC=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1N[C@@H]1CC[C@@H](N)CC1 Chemical compound C1=C(OC)C(OC)=CC=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1N[C@@H]1CC[C@@H](N)CC1 WEXXUEOCMIXDOW-WKILWMFISA-N 0.000 claims 1
- VQGDLSVXTDVKSH-IYARVYRRSA-N C1=C(OC)C(OC)=CC=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1N[C@@H]1CC[C@@H](NC(C)=O)CC1 Chemical compound C1=C(OC)C(OC)=CC=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1N[C@@H]1CC[C@@H](NC(C)=O)CC1 VQGDLSVXTDVKSH-IYARVYRRSA-N 0.000 claims 1
- WEXXUEOCMIXDOW-IYBDPMFKSA-N C1=C(OC)C(OC)=CC=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1N[C@H]1CC[C@@H](N)CC1 Chemical compound C1=C(OC)C(OC)=CC=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1N[C@H]1CC[C@@H](N)CC1 WEXXUEOCMIXDOW-IYBDPMFKSA-N 0.000 claims 1
- WDXIZGBVAFZCJY-WOVMCDHWSA-N C1=C(OC)C(OC)=CC=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1N[C@H]1CC[C@@H](O)CC1 Chemical compound C1=C(OC)C(OC)=CC=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1N[C@H]1CC[C@@H](O)CC1 WDXIZGBVAFZCJY-WOVMCDHWSA-N 0.000 claims 1
- GTJJTPQNWPTTGH-MAEOIBBWSA-N C1=C(OC)C(OCC)=CC(CNC(=O)C=2C(=CC=C(C=2)[N+]([O-])=O)N[C@H]2CC[C@@H](O)CC2)=C1 Chemical compound C1=C(OC)C(OCC)=CC(CNC(=O)C=2C(=CC=C(C=2)[N+]([O-])=O)N[C@H]2CC[C@@H](O)CC2)=C1 GTJJTPQNWPTTGH-MAEOIBBWSA-N 0.000 claims 1
- HVINKHLACGSDIH-QAQDUYKDSA-N C1=C(OC)C(OCC)=CC=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1N[C@@H]1CC[C@@H](N)CC1 Chemical compound C1=C(OC)C(OCC)=CC=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1N[C@@H]1CC[C@@H](N)CC1 HVINKHLACGSDIH-QAQDUYKDSA-N 0.000 claims 1
- QFVDWZKXOQZHFI-IYARVYRRSA-N C1=C(OC)C(OCC)=CC=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1N[C@@H]1CC[C@@H](NC=O)CC1 Chemical compound C1=C(OC)C(OCC)=CC=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1N[C@@H]1CC[C@@H](NC=O)CC1 QFVDWZKXOQZHFI-IYARVYRRSA-N 0.000 claims 1
- QUKFJIJDMRXLOM-MAEOIBBWSA-N C1=C(OC)C(OCC)=CC=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1N[C@H]1CC[C@@H](O)CC1 Chemical compound C1=C(OC)C(OCC)=CC=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1N[C@H]1CC[C@@H](O)CC1 QUKFJIJDMRXLOM-MAEOIBBWSA-N 0.000 claims 1
- NSGQKQIZLQSCAA-JCNLHEQBSA-N C1C[C@@H](O)CC[C@@H]1NC1=CC=C([N+]([O-])=O)C=C1C(=O)NCC1=CC=C(OCCO2)C2=C1 Chemical compound C1C[C@@H](O)CC[C@@H]1NC1=CC=C([N+]([O-])=O)C=C1C(=O)NCC1=CC=C(OCCO2)C2=C1 NSGQKQIZLQSCAA-JCNLHEQBSA-N 0.000 claims 1
- NPLGKRGZVLYRCP-KOMQPUFPSA-N C1C[C@@H](O)CC[C@@H]1NC1=CC=C([N+]([O-])=O)C=C1C(=O)NCC1=CC=C(OCO2)C2=C1 Chemical compound C1C[C@@H](O)CC[C@@H]1NC1=CC=C([N+]([O-])=O)C=C1C(=O)NCC1=CC=C(OCO2)C2=C1 NPLGKRGZVLYRCP-KOMQPUFPSA-N 0.000 claims 1
- BYKCACMHVDEYDP-PUZFROQSSA-N C1C[C@@H](O)CC[C@H]1NC1=CC=C([N+]([O-])=O)C=C1C(=O)NCC1=CC=CC2=CC=CC=C12 Chemical compound C1C[C@@H](O)CC[C@H]1NC1=CC=C([N+]([O-])=O)C=C1C(=O)NCC1=CC=CC2=CC=CC=C12 BYKCACMHVDEYDP-PUZFROQSSA-N 0.000 claims 1
- YACRNUFXUIQKNE-FZNQNYSPSA-N COC1=CC=C(Cl)C(CNC(=O)C=2C(=CC=C(C=2)[N+]([O-])=O)N[C@H]2CC[C@@H](O)CC2)=C1 Chemical compound COC1=CC=C(Cl)C(CNC(=O)C=2C(=CC=C(C=2)[N+]([O-])=O)N[C@H]2CC[C@@H](O)CC2)=C1 YACRNUFXUIQKNE-FZNQNYSPSA-N 0.000 claims 1
- 125000006312 cyclopentyl amino group Chemical group [H]N(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001856 erectile effect Effects 0.000 claims 1
- BAVGZNAVLYDCQK-UHFFFAOYSA-N n-(1,3-benzodioxol-5-ylmethyl)-2-(cyclopentylamino)-5-formylbenzamide Chemical compound C=1C=C2OCOC2=CC=1CNC(=O)C1=CC(C=O)=CC=C1NC1CCCC1 BAVGZNAVLYDCQK-UHFFFAOYSA-N 0.000 claims 1
- AHQMTRNJCXQXFI-ZDUSSCGKSA-N n-(1,3-benzodioxol-5-ylmethyl)-2-[[(2s)-1-hydroxybutan-2-yl]amino]-5-nitrobenzamide Chemical compound CC[C@@H](CO)NC1=CC=C([N+]([O-])=O)C=C1C(=O)NCC1=CC=C(OCO2)C2=C1 AHQMTRNJCXQXFI-ZDUSSCGKSA-N 0.000 claims 1
- IKTRZCFYCXNDQN-UHFFFAOYSA-N n-(1,3-benzodioxol-5-ylmethyl)-5-chloro-2-(cyclopentylamino)benzamide Chemical compound C=1C=C2OCOC2=CC=1CNC(=O)C1=CC(Cl)=CC=C1NC1CCCC1 IKTRZCFYCXNDQN-UHFFFAOYSA-N 0.000 claims 1
- FSJABZYVBDMQCO-GFCCVEGCSA-N n-(1,3-benzodioxol-5-ylmethyl)-5-cyano-2-[[(2r)-1-hydroxypropan-2-yl]amino]benzamide Chemical compound OC[C@@H](C)NC1=CC=C(C#N)C=C1C(=O)NCC1=CC=C(OCO2)C2=C1 FSJABZYVBDMQCO-GFCCVEGCSA-N 0.000 claims 1
- PLTNMABLWHRIHH-UHFFFAOYSA-N n-[(2-chloro-4-methoxyphenyl)methyl]-2-(cyclopentylamino)-5-nitrobenzamide Chemical compound ClC1=CC(OC)=CC=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1NC1CCCC1 PLTNMABLWHRIHH-UHFFFAOYSA-N 0.000 claims 1
- AKQPTQIPUHOABL-UHFFFAOYSA-N n-[(2-chlorophenyl)methyl]-2-(cyclopentylamino)-5-nitrobenzamide Chemical compound C=1C=CC=C(Cl)C=1CNC(=O)C1=CC([N+](=O)[O-])=CC=C1NC1CCCC1 AKQPTQIPUHOABL-UHFFFAOYSA-N 0.000 claims 1
- LDLUYLCLZNJZPJ-UHFFFAOYSA-N n-[(3,4-dimethoxyphenyl)methyl]-2-[(1-hydroxy-2-methylpropan-2-yl)amino]-5-nitrobenzamide Chemical compound C1=C(OC)C(OC)=CC=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1NC(C)(C)CO LDLUYLCLZNJZPJ-UHFFFAOYSA-N 0.000 claims 1
- MRIQTVUMKSJNAT-UHFFFAOYSA-N n-[(3,4-dimethoxyphenyl)methyl]-2-[(4-formamidocyclohexyl)amino]-5-nitrobenzamide Chemical compound C1=C(OC)C(OC)=CC=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1NC1CCC(NC=O)CC1 MRIQTVUMKSJNAT-UHFFFAOYSA-N 0.000 claims 1
- KMWLUXZPDXEDEZ-QZTJIDSGSA-N n-[(3,4-dimethoxyphenyl)methyl]-2-[[(1r,2r)-2-hydroxycyclopentyl]amino]-5-nitrobenzamide Chemical compound C1=C(OC)C(OC)=CC=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1N[C@H]1[C@H](O)CCC1 KMWLUXZPDXEDEZ-QZTJIDSGSA-N 0.000 claims 1
- ZISFCTXLAXIEMV-GFCCVEGCSA-N n-[(3,4-dimethoxyphenyl)methyl]-2-[[(2r)-1-hydroxypropan-2-yl]amino]-5-nitrobenzamide Chemical compound C1=C(OC)C(OC)=CC=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1N[C@H](C)CO ZISFCTXLAXIEMV-GFCCVEGCSA-N 0.000 claims 1
- BWWPCLTUPYWJJG-UHFFFAOYSA-N n-[(3-chloro-4-methoxyphenyl)methyl]-2-(1,3-dihydroxypropan-2-ylamino)-5-(trifluoromethyl)benzamide Chemical compound C1=C(Cl)C(OC)=CC=C1CNC(=O)C1=CC(C(F)(F)F)=CC=C1NC(CO)CO BWWPCLTUPYWJJG-UHFFFAOYSA-N 0.000 claims 1
- DQFCYKRNJINWRN-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-2-(cyclopentylamino)-5-nitrobenzamide Chemical compound C=1C=CC(Cl)=CC=1CNC(=O)C1=CC([N+](=O)[O-])=CC=C1NC1CCCC1 DQFCYKRNJINWRN-UHFFFAOYSA-N 0.000 claims 1
- UOZOSCXGTCTZDD-UHFFFAOYSA-N n-[(4-chloro-3-methoxyphenyl)methyl]-2-(1,3-dihydroxypropan-2-ylamino)-5-nitrobenzamide Chemical compound C1=C(Cl)C(OC)=CC(CNC(=O)C=2C(=CC=C(C=2)[N+]([O-])=O)NC(CO)CO)=C1 UOZOSCXGTCTZDD-UHFFFAOYSA-N 0.000 claims 1
- QYPHQNTXLWSFTG-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-2-(cyclopentylamino)-5-nitrobenzamide Chemical compound C=1C=C(Cl)C=CC=1CNC(=O)C1=CC([N+](=O)[O-])=CC=C1NC1CCCC1 QYPHQNTXLWSFTG-UHFFFAOYSA-N 0.000 claims 1
- YLMNFCVREAYQJM-UHFFFAOYSA-N n-benzyl-2-(cyclobutylamino)-5-nitrobenzamide Chemical compound C=1C=CC=CC=1CNC(=O)C1=CC([N+](=O)[O-])=CC=C1NC1CCC1 YLMNFCVREAYQJM-UHFFFAOYSA-N 0.000 claims 1
- DBRMUJGBCDLDQF-UHFFFAOYSA-N n-benzyl-2-(cyclohexylamino)-5-nitrobenzamide Chemical compound C=1C=CC=CC=1CNC(=O)C1=CC([N+](=O)[O-])=CC=C1NC1CCCCC1 DBRMUJGBCDLDQF-UHFFFAOYSA-N 0.000 claims 1
- ICWMIGWARJGJHC-UHFFFAOYSA-N n-benzyl-2-(cyclopropylamino)-5-nitrobenzamide Chemical compound C=1C=CC=CC=1CNC(=O)C1=CC([N+](=O)[O-])=CC=C1NC1CC1 ICWMIGWARJGJHC-UHFFFAOYSA-N 0.000 claims 1
- DSANIFSBCGWPLC-UHFFFAOYSA-N n-benzyl-2-[(2-hydroxycyclohexyl)amino]-5-nitrobenzamide Chemical compound OC1CCCCC1NC1=CC=C([N+]([O-])=O)C=C1C(=O)NCC1=CC=CC=C1 DSANIFSBCGWPLC-UHFFFAOYSA-N 0.000 claims 1
- YEKDPUWGQXOPME-QZTJIDSGSA-N n-benzyl-2-[[(1r,2r)-2-hydroxycyclopentyl]amino]-5-nitrobenzamide Chemical compound O[C@@H]1CCC[C@H]1NC1=CC=C([N+]([O-])=O)C=C1C(=O)NCC1=CC=CC=C1 YEKDPUWGQXOPME-QZTJIDSGSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000005932 reductive alkylation reaction Methods 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 description 15
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 description 9
- 125000004430 oxygen atom Chemical group O* 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 125000004434 sulfur atom Chemical group 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 2
- 150000008041 alkali metal carbonates Chemical class 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000005333 aroyloxy group Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 150000003016 phosphoric acids Chemical class 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- SNUSZUYTMHKCPM-UHFFFAOYSA-N 1-hydroxypyridin-2-one Chemical compound ON1C=CC=CC1=O SNUSZUYTMHKCPM-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- RQFCJASXJCIDSX-UHFFFAOYSA-N 14C-Guanosin-5'-monophosphat Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(O)=O)C(O)C1O RQFCJASXJCIDSX-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- GRWKNBPOGBTZMN-UHFFFAOYSA-N 2-benzyl-3-phenylpropane-1,2-diamine Chemical compound C=1C=CC=CC=1CC(N)(CN)CC1=CC=CC=C1 GRWKNBPOGBTZMN-UHFFFAOYSA-N 0.000 description 1
- IKCLCGXPQILATA-UHFFFAOYSA-N 2-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-N 0.000 description 1
- NSTREUWFTAOOKS-UHFFFAOYSA-N 2-fluorobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1F NSTREUWFTAOOKS-UHFFFAOYSA-N 0.000 description 1
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- SLAMLWHELXOEJZ-UHFFFAOYSA-N 2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- JYVPUGQZJRFFAF-UHFFFAOYSA-N 4,5-dimethyl-1h-pyrazol-3-amine Chemical compound CC=1NN=C(N)C=1C JYVPUGQZJRFFAF-UHFFFAOYSA-N 0.000 description 1
- IGIJSFNBEUBMGB-UHFFFAOYSA-N 4-(cyclohexyliminomethylideneamino)-n,n-diethylcyclohexan-1-amine Chemical compound C1CC(N(CC)CC)CCC1N=C=NC1CCCCC1 IGIJSFNBEUBMGB-UHFFFAOYSA-N 0.000 description 1
- LRDIEHDJWYRVPT-UHFFFAOYSA-N 4-amino-5-hydroxynaphthalene-1-sulfonic acid Chemical compound C1=CC(O)=C2C(N)=CC=C(S(O)(=O)=O)C2=C1 LRDIEHDJWYRVPT-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102100023245 Asparagine-tRNA ligase, cytoplasmic Human genes 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- HDFFVHSMHLDSLO-UHFFFAOYSA-N Dibenzyl phosphate Chemical compound C=1C=CC=CC=1COP(=O)(O)OCC1=CC=CC=C1 HDFFVHSMHLDSLO-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- ASMQGLCHMVWBQR-UHFFFAOYSA-N Diphenyl phosphate Chemical compound C=1C=CC=CC=1OP(=O)(O)OC1=CC=CC=C1 ASMQGLCHMVWBQR-UHFFFAOYSA-N 0.000 description 1
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 1
- 101000624939 Homo sapiens Asparagine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- QPQGTZMAQRXCJW-UHFFFAOYSA-N [chloro(phenyl)phosphoryl]benzene Chemical compound C=1C=CC=CC=1P(=O)(Cl)C1=CC=CC=C1 QPQGTZMAQRXCJW-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 125000002529 biphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C12)* 0.000 description 1
- NNTOJPXOCKCMKR-UHFFFAOYSA-N boron;pyridine Chemical compound [B].C1=CC=NC=C1 NNTOJPXOCKCMKR-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003222 cGMP degradation Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- VLNZUSMTOFYNPS-UHFFFAOYSA-N diethylphosphorylformonitrile Chemical compound CCP(=O)(CC)C#N VLNZUSMTOFYNPS-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 125000005905 mesyloxy group Chemical group 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- VMESOKCXSYNAKD-UHFFFAOYSA-N n,n-dimethylhydroxylamine Chemical compound CN(C)O VMESOKCXSYNAKD-UHFFFAOYSA-N 0.000 description 1
- LWFWUJCJKPUZLV-UHFFFAOYSA-N n-trimethylsilylacetamide Chemical compound CC(=O)N[Si](C)(C)C LWFWUJCJKPUZLV-UHFFFAOYSA-N 0.000 description 1
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000003431 oxalo group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- CMPQUABWPXYYSH-UHFFFAOYSA-N phenyl phosphate Chemical compound OP(O)(=O)OC1=CC=CC=C1 CMPQUABWPXYYSH-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 125000003367 polycyclic group Polymers 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- XKMLYUALXHKNFT-UHFFFAOYSA-N rGTP Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O XKMLYUALXHKNFT-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 125000005425 toluyl group Chemical group 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920001567 vinyl ester resin Polymers 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
[SEY ; ) ow
TL WO 99/54284 PCT/JP99/02028
ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE
S Technical Field
This invention relates to novel anthranilic acid derivatives having pharmacological activity, to a process for their production, to a pharmaceutical composition containing the same, and to their use as a medicament.
It is known that a cyclic guanosine-3',5'-monophosphate (hereinafter referred to as cGMP) derived from a guanosine-5'- triphosphate possesses a relaxant activity of smooth muscle and that a cyclic guanosine-3',5'-monophosphate phosphodiesterase (hereinafter refereed to as cGMP-PDE] acts to catalyze the degradation of cGMP to a guanosine-5'-monophosphate. The compounds having an inhibitory activity of cGMP-PDE are disclosed in European Patent Publication Nos. 579,496; 534,443; 526,004; 636,626; United States Patent Nos. 3,819,631; 5,294,612; 5,488,055; International Patent Publication Nos. 93/07,124;94/19,351; 95/18,097; 96/32,379; Japan Patent
Publication Nos. 05-222,000; 07-330,777; and so on.
Disdl 1 .
This invention relates to novel anthranilic acid derivatives, which have pharmaceutical activity such as inhibiting activity of cGMP-PDE, to a process for their production, to a pharmaceutical composition containing the same and to a use thereof.
Accordingly, one object of this invention is to provide the novel anthranilic acid derivatives, which have an inhibiting activity of cGMP-
PDE.
Another object of this invention is to provide a process for production of the anthranilic acid derivatives.
A further object of this invention is to provide a pharmaceutical composition containing, as an active ingredient, an anthranilic acid
TTT Ta ; derivative.
Still further object of this invention is to provide a use of the anthranilic acid derivatives for treating or preventing various diseases.
S The new anthranilic acid derivatives of this invention can be represented by the following formula (J) : 0
SAL
YASH ® 2
R R4 wherein
R! is hydrogen atom or a halogen atom;
R2 is an electron withdrawing group;
R3 is hydrogen atom; hydroxy group; a lower alkoxy group; a cycloalkyl group; a substituted or unsubstituted aryl group; or an unsaturated heterocyclic group optionally substituted with lower alkyl;
A is a lower alkylene group;
R4 is a lower alkoxy group, a substituted or unsubstituted, saturated or unsaturated heterocyclic group, an amino group optionally substituted with halo(lower)alkyl or : lower alkyl, } 30 a group -CH2-RS wherein RS is a cycloalkyl group or an unsaturated : heterocyclic group, or a group -CRSR7Ré wherein
Ré and R7” are each independently carboxy group,
vos WO 99/54284 PCT/JP99/02028 a protected carboxy group, a carbamoyl group optionally substituted with lower alkyl, or a lower alkyl group optionally substituted with one or > more substituents selected from the group consisting of halogen atom; hydroxy group; cyano group; azido group; lower alkoxy group; lower alkylthio group; protected carboxy group; lower alkanesulfonyl group; acyloxy group; lower alkanesulfonyloxy group; aryl group; aryloxy group which may be substituted with cyano; unsaturated heterocyclic group which may be substituted with lower alkyl; guanidino group which : may be substituted with lower alkyl, cyano and/or halogen; isothioureido group which may be substituted with lower alkyl and/or cyano; and amino group which may be substituted with acyl, protected carboxy, lower alkanesulfonyl, lower alkanesulfonyloxy or aryloxycarbonyl, or :
R¢ and R7 together with the carbon atom to which Ré and R7 are attached may form a substituted or unsubstituted, saturated carbocyclic group, or an unsaturated carbocyclic group optionally substituted with hydroxy, and
Ré8 is hydrogen atom; a lower alkoxy group; or a lower alkyl group optionally substituted with hydroxy or lower alkoxy; provided that when R* is the group -CRSR7R8 wherein
R6 is a lower alkyl group optionally substituted with halogen,
R7 is a lower alkyl group optionally substituted with halogen, and R8 is hydrogen atom or a lower alkyl group, or when R# is the group -CH2-RS wherein RS is the same as the above,
R3 should be hydrogen atom, hydroxy group or a cycloalkyl group; and a pro-drug thereof, and a salt thereof.
The compounds of the formula (I) may contain one or more asymmetric centers and thus they can exist as enantiomers or diastereoisomers.
The compounds of the formula (I) may also exist in tautomeric forms and the invention includes both mixtures and separate individual tautomers.
It is further to be noted that isomerization or rearrangement of the compounds (I) may occur by the effect of light, acid, base or the like, and the compounds obtained as the result of said isomerization or rearrangement are also included within the scope of the present invention.
The compounds of the formula (I) and its salts can be in the form of a solvate, which is included within the scope of the present invention.
The solvate preferably include a hydrate and an ethanolate. ~ 15 Also included in the scope of invention are radiolabelled derivatives of compounds of formula (I) which are suitable for biological studies.
According to this invention, the object compounds (I) or its salts can be prepared by the following process.
Process 1
Oo . 0]
H.N—R .
EN NAR 2 (am EN nA Re
R'-¢ _ H _— Rw Pe H
SFE or its salt 7 NH
R? R? Le 0 O or its saft or its sat }
Process 2
Oo (0) ap? » Sy on HNTATR A! > 0a - —_— -
YP Lz by NH or its reactive i" NH
R* derivative at amino group, R* or its salt wv) 1) or its reactive derivative or its salt at carboxy group, or its salt 4
Co 1
I J
Process 3
O
0 J 0} 6 7 A x NARS R® RB’ (VD) ONE
R' H —_— R'- ” H {7 a
R R
A 7 =} R (VI) (I-1) or its salt or its salt
In the above formulae, R?, R?, R3, R4, RS, R7 and A are the same as those defined in the above. : Some of the starting materials are novel and can be prepared by the following processes.
Process A (0) 0 — A — 3 . of 50 HoN A—R (A) ot Se i -— _—> lv, pA F F or its reactive derivative A Z F
R? at amino group, R or its salt {vim {Im or its reactive derivative or its salt at carboxy group, or its salt ’
Process B 0) 1 lo) —_— ——— ee eee —_— g ¢ /~ NH, 7" NH
R? R? PN 8 7 x R R ( ) (IV-1) or its salt or its salt
S
Process C
Oo (o} _n4
YL A F or its reactive derivative NY. Z SNH
R? at amino group, R2 or its salt R*
X) mw or its salt
Process D 0 0] —-A-R? SAL
YF “No or its reactive derivative Lz NH
R2 H at amino group, R2 2 or its salt
X17 (\%] or its salt
In the above formulae, R!, R?, R3, R4, R6, R7and A are the same as those defined in the above, R is hydrogen atom or a lower alkyl group.
In the above and subsequent descriptions of the present specification, suitable examples and illustrations of the various definitions which the present invention includes within the scope are explained in detail in the following.
The term “lower” is intended to mean a group having 1 to 6 carbon atom(s), unless otherwise indicated.
Suitably the lower alkyl groups and lower alkyl moieties in the _ 30 terms of the halo{lower)alkyl, lower alkanesulfonyl, lower oo alkanesulfonyloxy, lower alkoxy, lower alkylthio, hydroxy(lower)alkyl, ar(lower)alkyl, ar(lower)alkoxy and ar(lower)alkoxycarbonyl groups may include straight or branched ones having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl,
ad . WO 99/54284 PCT/IP99/02028 pentyl, isopentyl, hexyl or the like, more suitably the ones having 1 to 4 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl or isobutyl.
Suitably the examples of the lower alkenyl groups include straight or branched ones having 2 to 6 carbon atoms, such as ethenyl,
S propenyl (i.e., allyl or 1-propenyl), butenyl, isobutenyl, pentenyl, hexenyl or the like.
Suitable lower alkylene groups and lower alkylene moieties in the lower alkylenedioxy group may include straight or branched ones having 1 to 6 carbon atoms, such as methylene, methylmethylene, ethylene, methylethylene, trimethylene, tetramethylene, 2- methyltrimethylene, pentamethylene, hexamethylene or the like, more suitably the ones having 1 to 3 carbon atoms.
Suitable examples of the acyl groups and acyl moieties in the term of the acyloxy group include aliphatic acyl groups such as lower alkanoyls (e.g., formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, oxalyl, succinyl or pivaloyl) and acyl groups containing an aromatic or heterocyclic ring such as aroyls (e.g., benzoyl, toluoyl, xyloyl or naphthoyl), ar(lower)alkanoyls (e.g., phenylacetyl or phenylpropionyl), ar(lowerjalkoxycarbonyls (e.g., benzyloxycarbonyl or phenethyloxycarbonyl), heterocyclic carbonyls (e.g., thenoyl or furoyl) and the like.
The cycloalkyl groups may include the ones having 3 to 7 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or the like.
Suitably the aryl groups and aryl moieties in the terms of the ar(lower)alkyl, ar(lower)alkoxy, aryloxy, aryloxycarbonyl and aroyloxy groups may be an aromatic group having 6 to 12 carbon atoms.
Specific examples thereof are phenyl, naphthyl, indenyl, azulenyl, biphenylenyl, fluorenyl and anthracenyl.
Suitable examples of the saturated carbocyclic groups may be the cycloalkyl groups as exemplified in the above.
Suitable examples of unsaturated carbocyclic groups may include cyclopentenyl, cyclohexenyl, cycloheptenyl, 2,3-dihydro-1H- indenyl, benzocyclohexyl and the like.
Suitable examples of the halogen atoms and halo moiety of the halo(lower)alkyl group may be fluorine, chlorine, bromine or iodine.
Suitable examples of the unsaturated heterocyclic group may include mono- or poly-cyclic groups containing at least one hetero atom selected from nitrogen, sulfur and oxygen atoms, such as
S (1) unsaturated 3 to 7-membered, preferably S or 6-membered heteromonocyclic groups containing 1 to 4 nitrogen atoms, for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl [e.g., 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl or 2H- 1,2,3-triazolyl], tetrazoly! [e.g., 1H-tetrazoly or 2H-tetrazolyl] or the like.; (2) unsaturated 3 to 7-membered, preferably 5S or 6-membered heteromonocyclic groups containing an oxygen atom, for example, pyranyl or fury}; (3) unsaturated 3 to 7-membered, preferably 5 or 6-membered heteromonocyclic groups containing 1 to 2 sulfur atoms, for example, thienyl or the like; 4) unsaturated 3 to 7-membered, preferably 5 or 6-membered heteromonocyclic groups containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, oxazolyl, isoxazolyl, oxadiazolyl [e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl or 1,2,5-oxadiazolyl] or the like; (5) unsaturated 3 to 7-membered, preferably 5 or 6-membered heteromonocyclic groups containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example, thiazolyl, thiadiazolyl [e.g., 1,2,4- thiadiazolyl, 1,3,4-thiadiazolyl or 1,2,5-thiadiazolyl] or the like; (6) unsaturated condensed heterocyclic groups containing 1 to 2 nitrogen atoms, for example, indolyl, indazolyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl, benzimidazolyl or the like; (7) unsaturated condensed heterocyclic groups containing 1 to 2 oxygen atoms, for example, benzofuryl or the like; (8) unsaturated condensed heterocyclic groups containing 1 to 2 sulfur atoms, for example, benzo[blthienyl or the like;
B 9) unsaturated condensed heterocyclic groups containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, benzoxazolyl, : benzoxadiazolyl, phenoxazinyl or the like; (10) unsaturated condensed heterocyclic groups containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example, benzothiazolyl,
ren A WO 99/54284 PCT/JP99/02028 benzoisothiazolyl, phenothiazinyl or the like.
Suitable examples of the saturated heterocyclic group and heterocyclic moiety in the saturated heterocyclic sulfonyl group include monocyclic groups containing at least one hetero atom selected from 5) nitrogen, sulfur and oxygen atoms, such as (1) saturated 3 to 7-membered, preferably S or 6-membered heteromonocyclic groups containing 1 to 4 nitrogen atoms [e.g., pyrrolidinyl, imidazolidinyl, piperidyl or piperazinyl]; (2) saturated 3 to 7-membered, preferably 5 or 6-membered heteromonocyclic groups containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g., morpholinyl]; (3) saturated 3 to 7-membered, preferably 5 or 6-membered heteromonocyclic groups containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e.g., thiazolidinyl or thiomorpholinyl]; (4) saturated 3 to 7-membered, preferably 5 or 6-membered heteromonocyclic groups containing 1 to 2 sulfur atoms and/or 1 to 2 oxygen atoms [e.g., tetrahydrothiophenyl, tetrahydrothiopyranyl, 1- oxotetrahydrothiopyranyl, 1,1-dioxotetrahydrothiopyranyl, dioxacyclohexyl, tetrahydrofuranyl, tetrahydropyranyl or dioxanyl]; or the like.
Suitably carboxy protective groups in the protected carboxy group may include lower alkyl groups (e.g., methyl, ethyl or tert-butyl), halo(lower)alkyl groups (e.g., 2-iodomethyl or 2,2,2-trichloroethyl), ar(lower)alkyl groups (e.g., benzyl, trityl, 4-methoxybenzyl, 4-nitrobenzyl, phenethyl, bis(methoxyphenyl)methyl, 3,4-dimethoxybenzyl or 4- : hydroxy-3,5-di-tert-butylbenzyl), aryl groups (e.g., phenyl, naphthyl, tolyl or xylyl), and the like, more suitably the lower alkyl groups such as methyl, ethyl or tert-butyl and ar(lower)alkyl groups such as benzyl.
Specific examples of the each group containing the above- mentioned moiety and having substituent(s) are as follows.
As the halo{lower) alkyl group, fluoromethyl, iodomethyl, chloromethyl, trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2- trifluoroethyl, 2,2,2-trichloroethyl or the like may be mentioned.
The lower alkanesulfonyl group is methanesulfonyl(mesyl), ethanesulfonyl, propanesulfonyl or the like.
The lower alkanesulfonyloxy group is methansulfonyloxy(mesyloxy), ethanesulfonyloxy, propanesulfonyloxy or the like,
The lower alkoxy group is methoxy, ethoxy, propoxy, n-butoxy, tert-butoxy of the like.
The lower alkylthio group is methylthio, ethylthio, propylthio, butylthio, isobutylthio or the like.
The acyloxy group is formyloxy, acetyloxy, propionyloxy, benzoyloxy, toluoyloxy, naphthoyloxy, phenylacetyloxy, theonyloxys or the like.
The hydroxy(lower)alkyl group is hydroxymethyl, hydroxyethyl or the like. ‘15 The ar(lower)alkyl group is benzyl, 4-methoxybenzyl, 4- nitrobenzyl, phenethyl, trityl, bis(methoxyphenyl)methyl, 3,4- dimethoxybenzyl, 4-hydroxy-3,5-di-tert-butylbenzyl) or the like.
The ar(lower)alkoxy group is benzyloxy, 4-methoxybenzyloxy, 4- nitrobenzyloxy, phenethyloxy, trityloxy, bis(methoxyphenyl)methoxy, 3,4-dimethoxybenzyloxy, 4-hydroxy-3,5-di-tert-butylbenzyloxy or the like.
The lower alkylenedioxy group is methylenedioxy, ethylenedioxy and the like.
The aryloxy group is phenoxy, naphthoxy, tolyloxy, xylyloxy or the like,
The aroyloxy group is benzoyloxy, naphthoyloxy or the like.
The saturated heterocyclic sulfonyl group is piperazinesulfonyl, piperizinesulfonyl, morpholinesulfonyl, pyrazolidinesulfonyl or the like.
Preferred embodiments of the compounds (J) are those represented by the formula (I), wherein
R! is hydrogen atom or a halogen atom;
R? is an electron withdrawing group;
tan ® WO 99/54284 PCT/JP99/02028
R? is hydrogen atom; hydroxy group; a lower alkoxy group; a cycloalkyl group; a substituted or unsubstituted aryl group; or an unsaturated heterocyclic group optionally substituted with lower alkyl;
S A is a lower alkylene group;
R# is a lower alkoxy group, a substituted or unsubstituted, saturated or unsaturated heterocyclic group, an amino group optionally substituted with halo(lower)alkyl or lower alkyl, a group -CH2-RS wherein RS is a cycloalkyl group or an unsaturated heterocyclic group, or a group -CRSR7R8 wherein
R6 and R7 are each independently carboxy group, "a protected carboxy group, a carbamoyl group optionally substituted with lower alkyl, or a lower alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen atom; hydroxy group; cyano group; azido group; lower alkoxy group; lower alkylthio group; protected carboxy group; lower alkanesulfonyl group; acyloxy group; lower alkanesulfonyloxy group; aryl group; aryloxy group which may be substituted with cyano; unsaturated heterocyclic group which may be substituted with lower alkyl; guanidino group which may be substituted with lower alkyl, cyano and/or halogen; isothioureido group which may be substituted with lower alkyl and/or cyano; and amino group which may be substituted with acyl, protected carboxy, lower alkanesulfonyl, lower alkanesulfonyloxy or aryloxycarbonyl, or
RS and RY? together with the carbon atom to which R6 and R?
. co are attached may form a substituted or unsubstituted, saturated carbocyclic group, or an unsaturated carbocyclic group optionally substituted with hydroxy, and
S Re is hydrogen atom; a lower alkoxy group; or a lower alkyl group optionally substituted with hydroxy or a lower alkoxy; provided that when R¢* is the group ~-CRSR7R8 wherein
Ré¢ is a lower alkyl group optionally substituted with halogen,
R7 is a lower alkyl group optionally substituted with halogen, and R8 is hydrogen atom or a lower alkyl group, or when R? is the group -CH2-R5 wherein RS is the same as the above,
R3 should be hydrogen atom, hydroxy group or a cycloalkyl group, "15 the electron withdrawing group for R2 being selected from a group consisting of nitro group; cyano group; acyl group; halo(lower)alkyl group; sulfamoyl group; carbamoyl group optionally substituted with lower alkyl; halogen atom; lower alkenyl group optionally substituted with protected carboxy; lower alkanesulfonyl group; saturated heterocyclic sulfonyl group optionally substituted with protected carboxy; and unsaturated heterocyclic group, the substituent(s) on the aryl group for R3 being selected from a group consisting of lower alkyl group; halo(lower)alkyl group; lower alkylthio group; halogen atom; hydroxy group; lower alkylenedioxy group; cyano group; nitro group; carboxy group; protected carboxy group; sulfamoyl group; acyl group; aryl group; ar(lower)alkoxy group; aryloxy group; lower alkoxy group which may be substituted with lower alkoxy or cycloalkyl; amino group which may be substituted with acyl, protected carboxy or lower alkyl; and carbamoyl group which may be substituted with lower alkyl, the substituent(s) on the saturated or unsaturated heterocyclic group for
R4 being selected from a group consisting of oxo group; acyl group; protected carboxy group; lower alkanesulfonyl group; sulfamoyl group which may be substituted with protected carboxy; ar(lower)alkyl group; lower alkyl group which may be substituted with hydroxy or aryl; ureido
I WO 99/54284 PCT/JP99/02028 group which may be substituted with lower alkyl; guanidino group which may be substituted with protected carboxy; amidino group which may be substituted with protected carboxyl; and carbamoyl group which may be substituted with lower alkyl, and
S the substituent(s) on the saturated carbocyclic group formed by combination of Ré and R7 being selected from a group consisting of lower alkyl group; halogen atom; hydroxy group; lower alkoxy group; acyloxy group; carboxy group; protected carboxy group; oxo group; amidino group which may be substituted with protected carboxy; ureido group which may be substituted with lower alkyl or aryl; guanidino group which may be substituted with protected carboxy; amino group which may be substituted with acyl, lower alkanesulfonyl or protected carboxy; and carbamoyl group which may be substituted with lower alkyl or hydroxy(lower)alkyl; and a pro-drug thereof, and a salt thereof.
Another preferred embodiments are as follows: compounds of the formula (J), wherein
R! is hydrogen atom or a halogen atom;
R? is an electron withdrawing group;
R3 is a substituted or unsubstituted aryl group;
A is a lower alkylene group; and
R# is a group -CRSR7R8 wherein
R6 and R7 together with the carbon atom to which RS and R7 are attached may form a substituted or unsubstituted, saturated carbocyclic group, and
R8 is hydrogen atom; and compounds of the formula (I), wherein
R! is hydrogen atom or a halogen atom;
R? is an electron withdrawing group;
R3 is a substituted or unsubstituted aryl group;
A is a lower alkylene group; and
R¢4 is a group -CR6R7R8 wherein
Ré is a lower alkyl group substituted with hydroxy,
R7 is a lower alkyl which may be substituted with hydroxy, and
R8 is hydrogen atom or a lower alkyl group which may be substituted with hydroxy.
S Further preferred embodiments are as follows: compounds of the formula (I), wherein
R1is hydrogen atom or a halogen atom;
R? is nitro group, cyano group or a halo(lower)alkyl group;
R3 is an aryl group optionally substituted with one or more substituent(s) selected from halogen and lower alkoxy;
A is a lower alkylene group; and
R% 1s a group -CR6R7R8 wherein
Ré and R7 together with the carbon atom to which Ré and R7 are attached may form a saturated carbocyclic group optionally substituted with hydroxy or amino which may be substituted with acyl; and
R8 is hydrogen atom; and compounds of the formula (I), wherein
R! is hydrogen atom or a halogen atom;
R? is nitro group, cyano group or a halo(lower)atkyl group;
R3 is an aryl group optionally substituted with one or more substituent(s) selected from halogen and lower alkoxy;
A is a lower alkylene group; and
R# is a group -CRSR7R8 wherein
RS is a lower alkyl group substituted with hydroxy,
R7 is a lower alkyl group which may be substituted with hydroxy, and
R8 is hydrogen atom or a lower alkyl group which may be substituted with hydroxy. or In accordance with the invention, it includes salts of the compounds (I). The salts may be conventional non-toxic
Pharmaceutically acceptable salts, for example, a salt with an alkali metal (e.g., sodium or potassium) and an alkaline earth metal (e.g., calcium or magnesium), an ammonium, an organic base (e.g.,
-t WO 99/54284 PCT/JP99/02028 trimethylamine, triethylamine, pyridine, picoline, dicyclohexylamine or dibenzylethylenediamine), an organic acid (e.g., acetic acid, benzoic acid, succinic acid, fumaric acid, maleic acid, lactic acid, citric acid, tartaric acid, gluconic acid, methanesulfonic acid, benzenesulfonic acid, formic
S acid, p-toluenesulfonic acid or trifluoroacetic acid), inorganic acid (e.g., hydrogen chloride, hydrogen bromide, sulfuric acid or phosphoric acid), an amino acid (e.g., arginine, aspartic acid or glutamic acid) or the like.
The processes for preparing the starting compounds and the object compounds (I) of the present invention are explained in detail in the following,
Process 1
A compound (I) or its salt can be prepared by reacting a compound (II) or its salt with a compound (Ill) or its salt.
This reaction is usually carried out in the presence of an inorganic or an organic base.
Suitable inorganic base may include an alkali metal le.g., sodium or potassium], an alkali metal hydroxide [e.g., sodium hydroxide or potassium hydroxide}, an alkali metal hydrogen carbonate [e.g., sodium hydrogen carbonate or potassium hydrogen carbonate}, an alkali metal carbonate [e.g., sodium carbonate], an alkali earth metal carbonate [e.g., calcium carbonate}, an alkali metal hydride fe.g., sodium hydride or potassium hydride] and the like.
Suitable organic base may include tri(lower)alkylamines [e.g., triethylamine or N,N-diisopropylethylamine}, alkyl lithiums [e.g., methyl lithium or butyl lithium], lithium diisopropylamide, lithium hexamethyldisilazido and the like.
The reaction is usually carried out in a conventional solvent such as water, alcohols [e.g., methanol, ethanol or isopropyl alcohol], tetrahydrofuran, dioxane, toluene, methylene chloride, chloroform,
N,N-dimethylforrmamide or any other organic solvent which does not adversely affect the reaction, or a mixture thereof.
The reaction is preferably carried out at a temperature under cooling to warming. However, the reaction temperature is not limited.
Process 2
A compound (I) or its salt can be prepared by reacting a compound (IV) or its reactive derivative at the carboxy group, or its salt,
S with a compound (V) or its reactive derivative at the amino group, or its salt, according to a procedure known in the art.
Suitable reactive derivatives at the carboxy group of the compound (IV) may include the acid chloride, azide, acid anhydride, activated amide, activated ester and the like.
Suitably the acid anhydride may include anhydrides with an : acid such as substituted phosphoric acid (e.g., dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid or halogenated phosphoric acid), dialkylphosphorous acid, sulfuric acid, thiosulfuric acid, alkanesulfonic acid (e.g., methanesulfonic acid or ethanesulfonic acid), alkanoic acid (e.g., pivalic acid, pentanoic acid or isopentanoic acid), aromatic carboxylic acid (e.g., benzoic acid, chlorobenzoic acid, fluorobenzoic acid or nitrobenzoic acid),or the like.
Suitably the active amide may include the imidazoylylamide, 4- substituted imidazoylylamide, dimethylpyrazolylamide, triazolylamide tetrazolylamide or the like.
Suitably the active ester may include the dimethyliminomethyl [(CHj)2N*=CH-] ester, vinyl ester, propargyl ester, 4-nitrophenyl ester, 2,4-dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, pentafluorophenyl ester, methanesulfonylphenyl ester, phenyl thioester, p-nitrophenyl thioester, carboxymethyl thioester, pyranyl ester, pyridyl ester, 8-quinolyl thioester, an ester with a N-hydroxy compound (e.g.,
N,N-dimethylhydroxylamine, 1-hydroxy-2H-pyridone, N- hydroxysuccinimide, N-hydroxybenzotriazole or N-hydroxyphthalimide) or the like.
Suitably the reactive derivative at amino group of the compound : oo (V) may include Schiff's base type imino or its tautomeric enamine type isomer formed by the reaction of the compound (V) with a carbonyl compound such as aldehyde, ketone or the like; a silyl derivative formed by the reaction of the compound (V) with a silylating reagent such as . 35 trimethylsilylchloride, N ,O-bis(trimethylsilyljacetamide, N-
Ct WO 99/54284 PCT/JP99/02028 trimethylsilylacetamide or the like.
Each reactive derivative of compounds (IV) and (V) can optionally be selected from the above according to the kinds of the compounds (IV) and (V) to be used, respectively.
S When the compound (IV) is used in a free acid form or its salt form in the reaction, the reaction is preferably carried out in the presence of a condensing agent.
Suitable condensing agent may include carbodiimides (e.g.,
N,N-dicyclohexylcarbodiimide, N-cyclohexyl-N'-(4- diethylaminocyclohexyl)carbodiimide or N-ethyl-N'-(3- dimethylaminopropyl)carbodiimide or its hydrochloride), diphenylphosphinic azide, diphenylphosphinic chloride, diethylphosphoryl cyanide, bis(2-o0xo0-3-oxazolidinyl)phosphinic chloride,
N,N'-carbonyldiimidazole, 2-ethoxy- 1-ethoxycarbonyl-1,2- dihydroquinoline, cyanuric chloride or the like.
The reaction may be also carried out in the presence of an organic or inorganic base such as an alkali metal carbonate, trilower)alkylamine, pyridine, N- (lower) alkylmorphorine or the like.
The reaction is usually carried out in a conventional solvent such as water, acetone, alcohols [e.g., methanol, ethanol or isopropyl alcohol], tetrahydrofuran, dioxane, toluene, methylene chloride, chloroform, N,N'-dimethylformamide or any other organic solvent which does not adversely affect the reaction, or a mixture thereof.
The reaction is preferably carried out at a temperature under cooling to warming. However, the reaction temperature is not limited.
Process 3
A compound (I-1) or its salt can be prepared by reacting a compound (VI) or its salt with a ketone compound (VI]) in the presence of an inorganic acid (e.g., sulfuric acid or hydrogen chloride) or an organic acid (e.g., acetic acid) and a reducing agent.
Suitable reducing agent may include sodium cyanoborohydride, sodium triacetoxyborohydride, sodium borohydride, borane-pyridine complex and the like.
The reaction is usually carried out in a conventional solvent
Claims (17)
1. A compound of the formula (I): S Q A gi N al K [ F (0 [7 R RB wherein R! is hydrogen atom or a halogen atom; R2 is an electron withdrawing group; R3 is hydrogen atom; hydroxy group; a lower alkoxy group; a cycloalkyl group; a substituted or unsubstituted aryl group; or an unsaturated heterocyclic group optionally substituted with lower alkyl; A is a lower alkylene group; R4 is a lower alkoxy group, a substituted or unsubstituted, saturated or unsaturated heterocyclic group, an amino group optionally substituted with halo(lower)alkyl or lower alkyl, a group -CHz-R5 wherein RS is a cycloalkyl group or an unsaturated heterocyclic group, or a group -CRSR7R8 wherein R6 and R7 are each independently carboxy group, a protected carboxy group, a carbamoyl group optionally substituted with lower alkyl, or
! L . Ld a lower alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen atom; hydroxy group; cyano group; azido group; lower alkoxy group; lower alkylthio group; S protected carboxy group; lower alkanesulfonyl group; acyloxy group; lower alkanesulfonyloxy group; aryl group; aryloxy group which may be substituted with cyano; unsaturated heterocyclic group which may be substituted with lower alkyl; guanidino group which may be substituted with lower alkyl, cyano and/or halogen; isothioureido group which may be substituted with lower alkyl and/or cyano; and amino group which may be substituted with acyl, protected carboxy, lower alkanesulfonyl, lower alkanesulfonyloxy or aryloxycarbonyl, or Ré and R7 together with the carbon atom to which R® and R” are attached may form a substituted or unsubstituted, saturated carbocyclic group, or an unsaturated carbocyclic group optionally substituted with hydroxy, and RS is hydrogen atom; a lower alkoxy group; or a lower alkyl group optionally substituted with hydroxy or a lower alkoxy; provided that when R* is the group -CR6R7R8 wherein RS is a lower alkyl group optionally substituted with halogen, R7 is a lower alkyl group optionally substituted with halogen, and R8 is hydrogen atom or a lower alkyl group, or : when R# is the group -CH;-RS wherein RS is the same as the above, R3 should be hydrogen atom, hydroxy group or a cycloalkyl group; and a pro-drug thereof, and a salt thereof.
2. A compound of claim 1, wherein the electron withdrawing group for R? is selected from a group consisting
¥ of nitro group; cyano group; acyl group; halo(lowerjalkyl group; sulfamoyl group; carbamoyl group optionally substituted with lower alkyl; halogen atom; lower alkenyl group optionally substituted with protected carboxy; lower alkanesulfonyl group; saturated heterocyclic ) sulfonyl group optionally substituted with protected carboxy; and unsaturated heterocyclic group, the substituent(s) on the aryl group for R3 is/are selected from a group consisting of lower alkyl group; halo(lower)alkyl group; lower alkylthio group; halogen atom; hydroxy group; lower alkylenedioxy group; cyano group; nitro group; carboxy group; protected carboxy group; sulfamoyl group; acyl group; aryl group; ar(lower)alkoxy group; aryloxy group;
lower alkoxy group which may be substituted with lower alkoxy or cycloalkyl; amino group which may be substituted with acyl, protected carboxy or lower alkyl; and carbamoyl group which may be substituted with lower alkyl, the substituent(s) on the saturated or unsaturated heterocyclic group for R+ is/are selected from a group consisting of oxo group; acyl group;
protected carboxy group; lower alkanesulfonyl group; sulfamoyl group which may be substituted with protected carboxy; ar(lower)alkyl group; lower alkyl group which may be substituted with hydroxy or aryl; ureido group which may be substituted with lower alkyl, guanidino group which may be substituted with protected carboxy; amidino group which may be substituted with protected carboxyl; and carbamoyl group which may be substituted with lower alkyl, and the substituent(s) on the saturated carbocyclic group formed by combination of R6 and R7 is/are selected from a group consisting of lower alkyl group; halogen atom; hydroxy group; lower alkoxy group; acyloxy group; carboxy group; protected carboxy group; oxo group; amidino group which may be substituted with protected carboxy; ureido group which may be substituted with lower alkyl or aryl; guanidino group which may be substituted with protected carboxy; amino group which may be substituted with acyl, lower alkanesulfonyl or protected carboxy; 177 _ ]
AJ and carbamoyl group which may be substituted with lower alkyl or hydroxy(lower)alkyl.
3. A compound of Claim 1, wherein R3 is a substituted or unsubstituted aryl group; R# is a group -CRéR’R8 wherein R6 and R7 together with the carbon atom to which R6 and R7 are attached may form a substituted or unsubstituted, saturated carbocyclic group, and : Ré8 is hydrogen atom.
4, A compound of Claim 3, wherein R2 is nitro group, cyano group or a halo(lower)alkyl group; R3 is an aryl group optionally substituted with one or more substituent(s) selected from halogen and lower alkoxy; R# is a group -CRSR7R8 wherein R6 and R7 together with the carbon atom to which Ré and R7 are attached may form a saturated carbocyclic group optionally substituted with hydroxy or amino which may be substituted with acyl; and R2 is hydrogen atom. - 25
5. A compound of Claim 4 which is N-(2-chlorobenzyl)-2-cyclopentylamino-5-nitrobenzamide, N-(3-chlorobenzyl)-2-(cyclopentylamino)-5-nitrobenzamide, N-{4-chlorobenzyl)-2-(cyclopentylamino)-5-nitrobenzamide, 2-(cyclopentylamino)-N-(2,4- dichlorobenzyl)-5-nitrobenzamide, 2-(cyclopentylamino)-N-(3,4-dichlorobenzyl)-5-nitrobenzamide, 2-cyclopentylamino-5-nitro-N-(1,3-benzodioxol- 5-ylmethyljbenzamide, 2-(cyclopentylamino)-N -(4-fluorobenzyl)-5-nitrobenzamide, 2-(cyclopentylamino)-N-(4-methoxybenzyl)-5-nitrobenzamide, N-(2-chloro-4-methoxybenzyl)-2-(cyclopentylamino)-5-nitrobenzamide, N-(4-bromobenzyl)-2-(cyclopentylamino)-5S-nitrobenzamide, ST 178 CL I" ~~
2-(cyclopentylamino)-5-nitro-N-phenethylbenzamide, 2-(cyclopentylamino)-5-nitro-N-(3-phenylpropyl)benzamide, N-benzyl-2-(cyclobutylamino)-5-nitrobenzamide, N-benzyl-2-cycloheptylamino-S-nitrobenzamide,
N-benzyl-2-(cyclohexylamino)-5-nitrobenzamide, N-benzyl-2-(trans<4-hydroxycyclohexylamino)-5-nitrobenzamide, 2-(trans-4-hydroxycyclohexylamino)-5-nitro-N-(1,3-benzodioxol-5-
ylmethyl)benzamide, 2-(cyclopentylamino)-N-(2,4-difluorobenzyl)-5-nitrobenzamide,
N-benzyl-2-(cyclopropylamino)-5-nitrobenzamide, N-benzyl-2-(2-hydroxycyclohexylamino)-5-nitrobenzamide, N-benzyl-2-(trans-2-hydroxycyclopentylamino)-5-nitrobenzamide, 2-(cyclopentylamino)-5-formyl-N-(1,3-benzodioxol-5-
ylmethyl)benzamide, :
2-(trans-2-hydroxycyclopentylamino)-5-nitro-N-(1,3-benzodioxol-5-
ylmethyl)benzamide, 2-[cis-4-(benzoyloxy)cyclohexylamino]-N-(3,4-dimethoxybenzyl)-5-
nitrobenzamide, 2-(cis4-benzoyloxycyclohexylamino)-5-nitro-N-(1,3-benzodioxol-5-
ylmethyl)benzamide,
N-(3,4-dimethoxybenzyl)-2-( trans-4-hydroxycyclohexylamino)-5- nitrobenzamide,
2-(cis4-hydroxycyclohexylamino)-5-nitro-N-(1,3-benzodioxol-5- ylmethyl)benzamide,
N-benzyl-2-(3-hydroxycyclopentylamino)-S-nitrobenzamide, 2-[3-(benzoyloxy)cyclopentylamino}-N-benzyl- 5-nitrobenzarmide, N-(3,4-dimethoxybenzyl)-2-(cis-4-hydroxycyclohexylamino)-5-
nitrobenzamide, 2-(trans-2-aminocyclohexylamino)-5-nitro-N-(1,3-benzodioxol-5-
ylmethyl)benzamide, N-(3-chloro-4-methoxybenzyl)-2-(cis-4-hydroxycyclohexylamino)- S5-
nitrobenzamide, 2-[cis4-(benzoyloxy) cyclohexylamino]-N-(3-chloro-4-methoxybenzyl)-5- nitrobenzamide,
. Ce
N-(3-chloro-4-methoxybenzyl)-2-(trans-4-hydroxycyclohexylamino)-5- nitrobenzamide, N-(3,4-dimethoxybenzyl)-2-(trans-2-hydroxycyclopentylamino)-5- nitrobenzamide, N-(3,5-dichloro-4-methoxybenzyl)-2-(trans-4-hydroxycyclohexylamino)- 5-nitrobenzamide, N-(3,4-ethylenedioxybenzyl)-2-(trans-4-hydroxycyclohexylamino)-5- nitrobenzamide, 2-(cis4-hydroxycyclohexylamino)-5S-nitro-N-(3,4,5- trimethoxybenzyl)benzamide, 2-{cis-4-(acetoxy)cyclohexylamino}-N-(3,4-dimethoxybenzyl)-S- nitrobenzamaide, 2-[(trans-4-aminocyclohexyl)amino]-N-(3,4-dimethoxybenzyl)-5- nitrobenzamide, 2-(cis4-hydroxycyclohexylamino)-N-(1-naphthylmethyl)-5- nitrobenzamide, 2-(trans-4-acetamidocyclohexylamino)-N-(3,4-dimethoxybenzyl)-5- nitrobenzamide, N-(3,4-dimethoxybenzyl)-2-[(trans4-formamidocyclohexyl)amino]-5- nitrobenzamide, N-(2-chloro-5-methoxybenzyl)-2-(cis4-hydroxycyclohexylamino)-5- nitrobenzamide, 2-(cis4-benzoyloxycyclohexylamino)- N-(3-fluoro-4-methoxybenzyl)-5- nitrobenzamide, N-(3-ethoxy-4-methoxybenzyl)-2-(cis4-hydroxycyclohexylamino)-5- nitrobenzamide, : N-(4-chloro-4-ethoxyb enzyl)-2-(cis-4-hydroxycyclohexylamino)-5-nitro- benzamide, N-(4-ethoxy-3 -methoxybenzyl)-2-(cis4-hydroxycyclohexylamino)-5- nitrobenzamide, 2-(trans-4-aminocyclohexylamino}-N- (4-ethoxy-3-methoxybenzyl)-5- nitrobenzamide, N-(4-ethoxy-3-methoxybenzyl) -2-(trans4-formamidocyclohexylamino}- 5-nitrobenzamide,
oT 5-cyano-2-(trans-<4-hydroxycyclohexylamino)-N-(1,3-benzodioxol-5- ylmethyl)benzamide, : 2-(cis4-formamidocyclohexylamino)-N-(3,4-dimethoxybenzyl)-5- nitrobenzamide, S 2-(cis-4-hydroxycyclohexylamino)-5-nitro-N-{(1S)-1- phenylethyl]benzamide, 5-bromo-N-(3-chloro-4-methoxybenzyl)-2- {cyclopentylamino)benzamide, 5-chloro-2-(cyclopentylamino)-N-(1,3-benzodioxol-5- ylmethyl)benzamide, 4-chloro-N-(3,4-dimethoxybenzyl)-5S-fluoro-2-(trans-4- hydroxycyclohexylamino)benzamide, or 2-(cis4-aminocyclohexylamino)-N-(3,4-dimethoxybenzyl)-5- nitrobenzamide, or a salt thereof.
6. A compound of Claim 1, wherein R3 is a substituted or unsubstituted aryl group; R4 is a group -CRSR’R8 wherein : RS is a lower alkyl group substituted with hydroxy, R7 is a lower alkyl which may be substituted with hydroxy, and R8 is hydrogen atom or a lower alkyl group which may be substituted with hydroxy.
7. A compound of Claim 6, wherein R2? is nitro group, cyano group or a halo(lower}alkyl group; and R3 is an aryl group optionally substituted with one or more substituent(s) selected from halogen and lower alkoxy.
8. A compound of Claim 7 which is N-benzyl-2-[2-hydroxy- 1-(hydroxymethyljethylamino]-5- nitrobenzamide,
! '
‘ . : R)-2-( 1-ethyl-2-hydroxyethylamino)-5-nitro-N-(1 ,3-benzodioxol-5- ylmethyl)benzamide, (S)-2-[1 - (hydroxymethyl) propylamino]-5-nitro-N -(1,3-benzodioxol-5- ylmethyl)benzamide, 5) (R)-2-(2-hydroxy-1 -methylethylamino)-5-nitro-N-(1,3-benzodioxol-5- ylmethyl)benzamide, 2-[2-hydroxy-1,1 -bis(hydroxymethyl)ethylamino}-S-nitro-N-(1,3- benzodioxol-5-ylmethyl)benzamide, 2-(2-hydroxy-1,1 -dimethylethylamino)-S-nitro-N-(1 ,3-benzodioxol-5- ylmethyl)benzamide, 2-[2-hydroxy-1- (hydroxymethyl)ethylamino]- 5-nitro-N-(1,3-benzodioxol- 5-ylmethyl)benzamide, 2-[2-hydroxy-1-(hydroxymethyl)-1 -methylethylamino}-5-nitro-N-(1,3- benzodioxol-5-ylmethyl)benzamide, (S)-2-[1-(hydroxymethyl) -2-methylpropylamino}-5-nitro-N-(1,3- benzodioxol-5-ylmethyl)benzamide, 2-[(1R, 2R })-2-hydroxy- 1-(hydroxymethyl)propylamino]-5-nitro-N-(1 ,3- benzodioxol-5-ylmethyl)benzamide, N- (3-chloro-4-methoxybenzyl)-2-[2 -hydroxy-1-(hydroxy- methyl)ethylamino}-5-nitrobenzamide, 2-[1- {(hydroxyethyl)pentylamino}- 5-nitro-N-(1,3-benzodioxol-5- ylmethyl)benzamide, (R)-N-(3,4-dimethoxybenzyl) -2-(2-hydroxy-1 -methylethylamino)-5- nitrobenzamide, (S)-N-(3,4-dimethoxybenzyl)-2-[1- (hydroxymethyl)propylamino}-5- nitrobenzamide, N-(3,4-dimethoxybenzyl)-2- (2-hydroxy-1,1 -dimethylethylamino)-5- nitrobenzamide, N- (3-fluoro-4-methoxybenzyl) -2-[2-hydroxy-1- (hydroxymethyl) ethylamino]-5-nitrobenzamide, N-(4-chloro-3-methoxybenzyl)-2- [2-hydroxy-1- (hydroxymethyl) ethylamino]-5-nitrobenzamide, . 2-[2-hydroxy-1- (hydroxymethyljethylamino]-N-(2-naphthylmethyl)-5- nitrobenzamide, 2-[2-hydroxy-1- (hydroxymethyl)ethylamino}-N-[2-(2-
> : he } WO 99/54284 PCT/JP99/02028 methoxyphenyljethyl}-5-nitrobenzamide, N-(3-chloro-4-flucrobenzyl)-2-[2-hydroxy-1- (hydroxymethyl)ethylamino]-5-nitrobenzamide, (S)-N-(3,4-dimethoxybenzyl)-2-(2-hydroxy- 1-methylethylamino)-5- ) nitrobenzamide, (S)-N-(3,5-dimethoxybenzyl)-2-(2-hydroxy- 1-methylethyljamino-5- nitrobenzamide, N-(3-chloro-4-methoxybenzyl)-2-[2-hydroxy-1- (hydroxymethyl)ethylamino]-5- (trifluoromethyl)benzamide, (R )-5-cyano-2-(2-hydroxy-1-methylethylamino)-N-{1,3-benzodioxol-5- ylmethyl)benzamide, (S )-5-cyano-N-(3,4-dimethoxybenzyl)-2-(2-hydroxy-1- methylethylamino)benzamide, (R)-5-cyano-N-(3,4-dimethoxybenzyl)-2-(2-hydroxy-1- methylethylamino)benzamide, or (R)-N-(4-chloro-3-methoxybenzyl)-5-cyano-2-(hydroxy-1- methylethylamino)benzamide, or a salt thereof.
9. A compound of Claim 1 for use as a medicament.
10. A process for preparing a compound of the formula : O sali 0 7 NH R R* wherein R! is hydrogen atom or a halogen atom; : R2 is an electron withdrawing group; R3 is hydrogen atom; hydroxy group; a lower alkoxy group; a cycloalkyl group; a substituted or unsubstituted aryl group; or an unsaturated heterocyclic group optionally substituted with lower
N | ~ . x t ’
alkyl; A is a lower alkylene group; R4 is a lower alkoxy group, a substituted or unsubstituted, saturated or unsaturated heterocyclic group, an amino group optionally substituted with halo{lower)alkyl or lower alkyl, a group -CH2-R5 wherein RS is a cycloalkyl group or an unsaturated heterocyclic group, or a group -CRSR’R® wherein R6 and R7 are each independently carboxy group, a protected carboxy group, a carbamoyl group optionally substituted with lower alkyl, or a lower alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen atom; hydroxy group; cyano group; azido group; lower alkoxy group; lower alkylthio group; protected carboxy group; lower alkanesulfonyl group; acyloxy group; lower alkanesulfonyloxy group; aryl group; aryloxy group which may be substituted with cyano; unsaturated heterocyclic group which may be substituted with lower alkyl; guanidino group which may be substituted with lower alkyl, cyano and/or halogen; isothioureido group which may be substituted with lower alkyl and/or cyano; and amino group which may be substituted with acyl, protected carboxy, lower alkanesulfonyl, lower alkanesulfonyloxy or an aryloxycarbonyl, or R6 and R7 together with the carbon atom to which R® and R? are attached may form a substituted or unsubstituted,
\ PY . B
Cs WO 99/54284 PCT/JP99/02028 saturated carbocyclic group, or an unsaturated carbocyclic group optionally substituted with hydroxy, and R8 is hydrogen atom; a lower alkoxy group; or a lower alkyl S group optionally substituted with hydroxy or lower alkoxy; provided that when R¢4 is the group -CRSR7R8 wherein Ré is a lower alkyl group optionally substituted with halogen, R7 is a lower alkyl group optionally substituted with halogen, and R8 is hydrogen atom or a lower alkyl group, or when R# is the group -CHa2-RS wherein RS is the same as the above, R3 should be hydrogen atom, hydroxy group or a cycloalkyl group; and a salt thereof, which comprises (1) reacting a compound of the formula (II) : 0) SAL LOY ONTR? Reg JH (m /~F R2 or its salt, with a compound of (II) HN-R* (mm) or its salt, wherein R!, R2, R3, R* and A are as defined above, or (2) reacting a compound of the formula (IV): O XY oH RT, av) / NH R he
§ - PCT/JP99/02028 or its salt, with a compound of the formula (V]. H,N—A-R® (V) or its salt, S wherein R!, R?, R?3, R¢ and A are as defined above, or (3) subjecting a compound of the formula (VI): O ~ NTRS R'— H C2 (VI) /~ NH, R2 or its salt, to reductive alkylation with a compound of formula (VII): 0) J vi [J 7 R R or its salt, wherein R!, R?, R3, R6, R7 and A are as defined above.
11. A pharmaceutical composition which comprises, as an active ingredient, a compound of Claim 1 or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable carrier.
12. A pharmaceutical composition comprising a compound of Claim 1, as an active ingredient, in association with a pharmaceutically acceptable, substantially non-toxic carrier or excipient.
13. A substance or composition for use in a method of treatment and/or prevention of angina, hypertension, pulmonary hypertension, congestive heart failure, glomerular diseases, renal tubulo- intestinal diseases, renal failure, atherosclerosis, conditions of reduced blood vessel potency, peripheral vascular disease, stroke, bronchitis, asthma, allergic rhinitis, urticaria, glaucoma, diseases characterized by disorders of gut motility, erectile dysfunction, female sexual dysfunction, impotence, diabetic complications, micturition disorder, or incontinence Or Storage of urine 186 AMENDED SHEET
". . PCT/JP99/02028 disorder, said substance or composition comprising a compound of Claim 1, and said method comprising administering said substance or composition.
14. A composition of Claim 11 for use in a method of treatment of erectile dysfunction or impotence.
15. A use of the compound of Claim 1 for the manufacture of a medicament for inhibiting cGMP-PDE.
16. A use of the compound of Claim 1 for the manufacture of a medicament for treatment and/or prevention of angina, hypertension, pulmonary hypertension, congestive heart failure, glomerular diseases, renal tubulo-intestinal diseases, renal failure, atherosclerosis, conditions of reduced blood vessel potency, peripheral vascular disease, stroke, bronchitis, asthma, allergic rhinitis, urticaria, glaucoma, diseases characterized by disorders of gut motility, erectile dysfunction, female sexual dysfunction, impotence, diabetic complications, micturition disorder, or incontinence or storage of urine disorder.
17. A method for the prevention of angina, hypertension, pulmonary hypertension, congestive heart failure, glomerular diseases, renal tubulo-intestinal diseases, renal failure, atherosclerosis, conditions of reduced blood vessel patency, peripheral vascular disease, stroke, bronchitis, asthma, allergic rhinitis, urticaria, glaucoma, diseases characterized by disorders of gut motility, erectile 187 AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPP3085A AUPP308598A0 (en) | 1998-04-20 | 1998-04-20 | Anthranilic acid derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200005243B true ZA200005243B (en) | 2002-01-14 |
Family
ID=3807344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200005243A ZA200005243B (en) | 1998-04-20 | 2000-09-28 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase. |
Country Status (2)
Country | Link |
---|---|
AU (1) | AUPP308598A0 (en) |
ZA (1) | ZA200005243B (en) |
-
1998
- 1998-04-20 AU AUPP3085A patent/AUPP308598A0/en not_active Abandoned
-
2000
- 2000-09-28 ZA ZA200005243A patent/ZA200005243B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AUPP308598A0 (en) | 1998-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6384080B1 (en) | Anthranilic acid derivatives as inhibitors of the cGMP-phosphodiesterase | |
EP1469851B1 (en) | Melanocortin receptor agonists | |
US6916812B2 (en) | Alpha-aminoamide derivatives as melanocortin agonists | |
JP3955211B2 (en) | Substituted 1-aminoalkyl lactams and their use as muscarinic receptor antagonists | |
WO2006018662A2 (en) | Aryl urea derivatives for treating obesity | |
JPH11512701A (en) | Selective β ▲ 3 ▼ adrenergic agonist | |
JP2008179624A (en) | Novel n-(2-aminophenyl)benzamide derivative having urea structure | |
US7410987B2 (en) | Method for treating pain or pruritis by administering κ-opioid receptor agonist comprising 2-phenylbenzothiazoline derivative | |
HUT61727A (en) | Process for producing 1-(2-arylethyl)-pyrrolidines and pharmaceutical compositions comprising same | |
CN1294576A (en) | VLA-4 antagonists | |
US20070259965A1 (en) | Acyclic 1,3-Diamine And Uses Therefor | |
JPH03101648A (en) | Renin inhibitor of peptidilaminodiols | |
ES2312461T3 (en) | DERIVATIVES OF TYROSINE AS INHIBITORS OF PHOSPHATASE. | |
WO2001030745A1 (en) | Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase | |
ZA200005243B (en) | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase. | |
JP2531329B2 (en) | New compound | |
US6277876B1 (en) | Matrix metalloproteinase inhibitors | |
JP4567889B2 (en) | ((Aminoiminomethyl) amino) alkanecarboxamide and its application in therapy | |
CN109843379B (en) | Substituted ureas and methods of making and using the same | |
JP3070812B2 (en) | New oxazolidine | |
KR100658962B1 (en) | Spiroimidazolidine derivatives, their preparation and pharmaceutical preparations comprising them | |
CZ20003897A3 (en) | Anthranilic acid derivatives | |
JPH03209356A (en) | Amino acid derivative | |
AU758298B2 (en) | Anthranilic acid derivatives as inhibitors of the cGMP-phosphodiesterase | |
JPH07242655A (en) | 1,4-benzodioxane derivative |